Diet Plus Inositols, α-Lactalbumin and Gymnema sylvestre: The Successful Combo to Restore Body Weight and Metabolic Profile in Obese and Dysmetabolic Patients

Nutrients. 2023 Jul 14;15(14):3142. doi: 10.3390/nu15143142.

Abstract

The primary control of dysmetabolic patients is extremely challenging worldwide, with inadequate dietary habits and sporadic physical activity among the key risk factors for metabolic syndrome onset. Nowadays, there is no exclusive treatment for this condition, and considering that preventive measures usually fail, new therapeutic approaches need to be proposed and investigated. This present pilot study compared the effects of diet alone and in association with a combination of myo-inositol and d-chiro-inositol in their 40:1 ratio, α-lactalbumin, and Gymnema sylvestre on different metabolic parameters in obese dysmetabolic patients. To this purpose, 37 patients with BMI between 30 and 40 and fasting blood glucose between 100 and 125 mg/dL were divided into two groups: (i) the control group followed a hypocaloric Mediterranean diet, (ii) while the study group was also supplemented with a daily dosage of two sachets, each one containing 1950 mg myo-inositol, 50 mg d-chiro-inositol, 50 mg α-lactalbumin, and 250 mg Gymnema Sylvestre. After a 6-month treatment, all parameters improved in both groups. Nevertheless, the treated group experienced a greater improvement, especially concerning the variation from the baseline of HOMA index, triglycerides, BMI, body weight, and waist circumference. These findings support the supplementation with myo-inositol and d-chiro-inositol in the 40:1 ratio, α-lactalbumin, and Gymnema sylvestre as a therapeutical strategy to potentiate the beneficial effects induced via dietary programs in dysmetabolic patients.

Keywords: Gymnema sylvestre; d-chiro-inositol; diet; gut microbiota; insulin-sensitizing effect; intestinal inflammation; lifestyle; myo-inositol; α-lactalbumin.

MeSH terms

  • Body Weight
  • Diet
  • Female
  • Gymnema sylvestre*
  • Humans
  • Inositol / therapeutic use
  • Lactalbumin / metabolism
  • Metabolome
  • Obesity / complications
  • Obesity / drug therapy
  • Pilot Projects
  • Polycystic Ovary Syndrome*

Substances

  • Lactalbumin
  • Inositol

Grants and funding

This research received no external funding. The APC was funded by Lo.Li. Pharma S.r.l., Rome, Italy.